102 Chapter 7 Table 1. Baseline characteristics of the training and validation cohort Training cohort (n=4208) Validation cohort (n=1052) Baseline characteristics No implant loss (n=3913) Implant loss (n=295) P-value No implant loss (n=993) Implant loss (n=59) P-value Age, years 47.9 ± 11.4 48.8± 11.2 0.079 48.7 ± 11.7 49.8 ± 11.9 0.455 BMI, L2/m 24.7 ± 4.2 25.7 ± 4.8 <0.001 24.7 ± 4.1 25.7 ± 4.2 0.085 ASA score 0.004 0.926 I 2186 (56.4) 135 (46.4) 545 (55.4) 33 (56.9) II 1546 (39.9) 138 (47.4) 394 (40.1) 23 (39.7) III 143 (3.7) 18 (6.2) 44 (4.5) 2 (3.4) IV 1 (0.0) 0 (0.0) 0 (0.0) 0 (0) Missing 37 4 10 1 Current smoker 383 (12.3) 55 (22.5) <0.001 88 (11.4) 8 (18.2) 0.178 Missing 791 51 224 15 Indication 0.476 Breast cancer 3170 (81.0) 234 (79.3) 798 (80.4) 49 (83.1) 0.613 Prophylactic 743 (19.0) 61 (20.7) 195 (19.6) 10 (16.9) Bilateral 1590 (40.6) 119 (40.3) 0.921 374 (37.7) 27 (45.8) 0.213 Previous radiotherapy 170 (4.9) 18 (6.8) 0.185 36 (4.1) 3 (5.7) 0.485 Missing 471 30 123 6 Preoperative antibiotics 3793 (97.6) 281 (93.1) 0.039 957 (97.3) 56 (96.6) 0.673 Missing 25 1 9 1 Antiseptic rinse 3067 (78.4) 224 (75.9) 0.538 755 (76.0) 47 (79.7) 0.606 Missing 34 2 13 0 Nipple guards 960 (24.5) 57 (19.3) 0.095 260 (26.2) 19 (32.2) 0.438 Missing 43 2 12 0 Type of reconstruction 0.327 0.388
RkJQdWJsaXNoZXIy MTk4NDMw